Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Arrowhead reported Q2 revenue of $73.7 million, down from the prior year, but significantly strengthened its balance sheet with total cash resources of approximately $1.78 billion following recent financings. Deferred revenue increased substantially to $157.2 million, indicating strong future revenue recognition potential despite the current period's reported figures. Commercially, REDEMPLO prescriptions grew 40% over the last four weeks to exceed 400 total, and the U.S. wholesale acquisition cost was raised to a premium $45,000 per patient.
Key figures
- Revenue
- 73737000
- Wac price
- $45,000
- Cash resources
- 1784091000
- Deferred revenue
- 157158000
- Madrigal upfront
- 25000000
- Offering proceeds
- 930000000
- Madrigal milestones
- 975000000
- Total prescriptions
- >400
- Prescription growth 4w
- 40%
- Obesity combo weight loss
- -9.4%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.